Tissue-restricted mTOR inhibition enabled by this binary pharmacology strategy reduced the toxicity in peripheral tissues but maintained therapeutic benefits of RapaLink-1 in glioblastoma xenograft models. This evidence concerns the gene MTOR and glioblastoma.